首页> 美国卫生研究院文献>Cancer Biology Therapy >LB100 a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential
【2h】

LB100 a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

机译:LB100一种PP2A的小分子抑制剂具有强大的化学和放射增敏潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that plays a significant role in mitotic progression and cellular responses to DNA damage. While traditionally viewed as a tumor suppressor, inhibition of PP2A has recently come to attention as a novel therapeutic means of driving senescent cancer cells into mitosis and promoting cell death via mitotic catastrophe. These findings have been corroborated in numerous studies utilizing naturally produced compounds that selectively inhibit PP2A. To overcome the known human toxicities associated with these compounds, a water-soluble small molecule inhibitor, LB100, was recently developed to competitively inhibit the PP2A protein. This review summarizes the pre-clinical studies to date that have demonstrated the anti-cancer activity of LB100 via its chemo- and radio-sensitizing properties. These studies demonstrate the tremendous therapeutic potential of LB100 in a variety of cancer types. The results of an ongoing phase 1 trial are eagerly anticipated.
机译:蛋白磷酸酶2A(PP2A)是一种丝氨酸/苏氨酸磷酸酶,在有丝分裂进程和细胞对DNA损伤的反应中起着重要作用。尽管传统上将PP2A视为一种肿瘤抑制因子,但近年来它已成为一种抑制衰老的新方法,可将衰老的癌细胞带入有丝分裂并通过有丝分裂灾难促进细胞死亡。这些发现已在许多利用选择性抑制PP2A的天然产生的化合物的研究中得到证实。为了克服与这些化合物有关的已知人类毒性,最近开发了一种水溶性小分子抑制剂LB100来竞争性抑制PP2A蛋白。这篇综述总结了迄今为止的临床前研究,这些研究已经证明了LB100的化学和放射增敏特性使其具有抗癌活性。这些研究证明了LB100在多种癌症类型中的巨大治疗潜力。迫切期望进行中的1期试验的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号